# OnCo record clinical-benefit-response (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/clinical-benefit-response/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "clinical-benefit-response" ;
  schema:name "Clinical benefit response (the gemcitabine trial endpoint)"@en ;
  schema:alternateName "CBR (pancreatic cancer)"@en, "Clinical benefit rate in pancreatic cancer"@en, "Burris endpoint"@en, "Composite endpoint of pain, performance status and weight"@en ;
  schema:description "Clinical benefit response was the measure invented for the 1997 trial that got gemcitabine approved for pancreatic cancer: a patient counted as benefiting if pain, painkiller use, day-to-day function or weight improved for at least four weeks without any of the others getting worse. It is a symptom endpoint, and it is why gemcitabine was accepted on a survival gain of about five weeks."@en ;
  schema:url <https://onco.cc/terms/clinical-benefit-response/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Gemcitabine> ;
  schema:citation <https://doi.org/10.1200/jco.1997.15.6.2403>, <https://doi.org/10.1056/nejmoa1809775> ;
  onco:tag "gi", "pancreatic" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/hazard-ratio/> ;
  onco:trials <https://onco.cc/trials/prodige-24/> .